Please reference the list below for active Phase I/Translational clinical research being conducted by Comprehensive Cancer Centers. If a research offering is of interest, Email Us. Please add either the study number or details about the study in your email for a more fast and efficient response.
| i2896 | A Phase 1 Study of SGN-B6A in Advanced Solid Tumors |
| i3209 | A Phase 1/2a Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors |
| i3257 | A multicenter, open-label phase 1/1b dose-finding, safety, and pharmacokinetic study of MBRC-101, an anti-Epha5 monomethyl auristatin E (MMAE) antibody drug conjugate, in advanced refractory solid tumors |
| i3316 | A Phase 1, First in Human, Dose Escalation and Expansion, Multicenter Study of XMT1660 in Participants with Solid Tumors |
| i3324 | A Multi-Center, Open-Label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of YL205 in Patients with Advanced Solid Tumors. |
| i3339 | A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors |
| i3351 | A Phase 1, Multicenter Trial of Subcutaneous Trastuzumab Deruxtecan in Participants with Metastatic Solid Tumors |
| i3359 | A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluatethe Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients with Advanced Solid Tumors |
| i3362 | A Phase 1b, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination with Toripalimab with or without Other Treatments in Participants with Advanced or Metastatic Solid Tumors. |
| i3369 | A First-in-Human (FIH), Open-Label, Phase Ia/Ib Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-DP in Subjects with Relapsed/Metastatic Solid Tumors. |
| i3376 | A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral Selective CDK2/4 Dual DegraderNKT5097 in Adults with Advanced/Metastatic Solid Tumors |
| i3383 | Phase I Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6043 in Patients with Advanced/Metastatic Solid Tumors. |
| Independent | A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer |
| Independent | A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL217 in Patients with Advanced Solid Tumors |
| Independent | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects with Advanced Solid Tumors. |
| SCRI 23099 | A Phase 1, first-in-human, open-label, multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors |